跳到正文
原文
The Lancet 柳叶刀· Riccardo Papa, Susan Rhee, Patricia Delai, Keqin Zhang, Ignacio Briceño Balcázar, Kavitha Rethanavelu, Toshifumi Fujiwara, Kenichi Mishima, Jacek Tabarkiewicz, Thomas Funck-Brentano, Raphaella Stander, Javier Bachiller-Corral, Kathryn M Dahir, E Marelise W Eekhoff, Matti Hero, Evelyn Kuong, Naoto Uemura, Meijian Zhou, Dinko Gonzalez Trotter, Jing Gu, Robert J Sanchez, Donal Óg O’Donovan, Aris N Economides, Robert Pordy, Boaz Hirshberg, George D Yancopoulos, Richard Keen, OPTIMA Study Group·· 2026-09-29精选AI 评分65

garetosmab 治疗进行性骨化性纤维发育不良的疗效与安全性:OPTIMA III 期随机双盲安慰剂对照试验

[Articles] Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial

AI 导读

garetosmab(activin A 阻断抗体)在 OPTIMA III 期随机双盲安慰剂对照试验中显著减少了进行性骨化性纤维发育不良(FOP)患者新发异位骨化病灶数量。研究认为这为其成为有效且总体耐受性良好的疾病修饰治疗提供了有力证据。

推荐理由

OPTIMA III 期随机双盲安慰剂对照试验显示 garetosmab 显著减少 FOP 患者新发异位骨化病灶数量,为该罕见遗传病提供了疾病修饰治疗的临床证据。

来源:The Lancet 柳叶刀 · thelancet.com